Clinical trial
Prognostic Value of Protein IMP3 Expression in Cervical Cancer
NCT05151159 is registered in ClinicalTrials.gov with University of Mostar as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prognostic Value of Protein IMP3 Expression in Cervical Cancer
- Lead sponsor
- University of Mostar
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 1, 2003
- Completion date
- December 31, 2022
- Enrollment
- 80 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
cervical carcinoma